Colorado State University researchers found that CBD caused cell death in glioblastoma, a rare and intractable form of brain cancer.

Cannabidoil (CBD) has emerged in recent years as an alternative medicine for hard-to-treat illnesses like epilepsy, with the Food and Drug Administration (FDA) approving cannabis-derived medications, like Epidiolex. Studies have also demonstrated cannabis as a possible supplemental treatment in cancer patients, though researchers caution there have been no definitive conclusions.

Those two trends influenced a new study, published in the FASEB Journal, that found CBD as an effective therapy in a rare form of intractable brain cancer called glioblastoma. A highly deadly disease with low survival rates, glioblastoma affects both humans and dogs. Once discovered, it spreads rapidly through the brain and proves difficult to slow down. This study, scheduled to be presented at medical conference canceled due to the coronavirus pandemic, provides a possible improvement in fighting glioblastoma.

“Further research and treatment options are urgently needed for patients afflicted by brain cancer,” Chase Gross, a student at Colorado State University’s Doctor of Veterinary Medicine/Master of Science program, said in a statement. “Our work shows that CBD has the potential to provide an effective, synergistic glioblastoma therapy option and that it should continue to be vigorously studied.”

Gross, alongside fellow CSU researchers, exposed human and canine glioblastoma cancer cells to variations of CBD. One test included a 100% pure CBD isolate while another used a CBD extract that included other natural cannabinoids, such as THC and CBG. Both versions of CBD proved successful in slowing the cancer’s overall cell growth and inducing apoptosis, or cell death.

Read the full article at TheFreshToast